Notably, NRAS and PTPN11 mutations are more prevalent in secondary AML than in higher-risk MDS, and the KRAS mutation is more frequent in higher-risk MDS than in lower-risk MDS, implying that RAS signaling abnormalities tend to occur in the late stage of MDS [187]. This evidence concerns the gene KRAS and acute myeloid leukemia.